Apheris Secures $8.25M to Revolutionize AI Data Access in Life Sciences

Apheris Raises $8.25M to Tackle AI Data Bottleneck in Life Sciences

Apheris, a Berlin-based startup, has successfully secured $8.25 million in Series A funding to advance its innovative federated computing platform. The investment round, led by OTB Ventures and eCAPITAL, brings the company's total funding to $20.8 million 1

1

2

2

. This significant financial boost aims to address a critical challenge in the AI-driven life sciences sector: accessing and utilizing sensitive health data while maintaining privacy and regulatory compliance.

The Data Dilemma in AI-Driven Life Sciences

Robin Röhm, co-founder of Apheris, identifies the core problem in building AI solutions for life sciences: the vast majority of health data remains unused due to patient privacy concerns, regulatory restrictions, and intellectual property protection 1

1

. This data bottleneck significantly hampers the potential of AI applications in healthcare and pharmaceuticals.

Federated Computing: A Secure Solution

Apheris's platform leverages federated computing to tackle this challenge. The technology allows computations to be executed locally where data resides, with only the outputs (such as model parameters) being aggregated centrally 1

1

. This approach enables secure access to sensitive data for AI model training without moving the data itself, thus preserving privacy and compliance.

The Apheris Compute Gateway

At the heart of Apheris's solution is the Compute Gateway, a software agent that acts as an interface between local data and AI models 1

1

2

2

. This gateway facilitates federated computing projects by allowing researchers to request access to datasets on a self-service basis. The platform incorporates advanced security features, including:

1. Homomorphic encryption: Enables queries on encrypted datasets without decryption 2

   2

2. Differential privacy: Enhances anonymization of personal information in shared datasets 2

   2

Industry Adoption and Use Cases

Apheris has already gained traction in the pharmaceutical industry, with customers including Roche, Johnson & Johnson, and several hospitals 1

1

2

2

. The platform is being used by the AI Structural Biology (AISB) Consortium, a collaborative initiative involving major pharmaceutical companies for AI-driven drug discovery 1

1

.

A Pivotal Shift in Strategy

Apheris's journey to this point involved a significant pivot in 2023. Originally founded in 2019 to build a federated learning framework competing with open-source approaches, the company shifted its focus to the data owner side, specifically targeting pharma and life sciences 1

1

. This strategic change has reportedly led to a fourfold increase in revenue since the launch of their new product in late 2023.

Future Prospects and Industry Impact

With the new funding, Apheris plans to hire senior talent with life science backgrounds and further develop its platform 1

1

. The company aims to become a critical component in the emerging ecosystem of federated data networks, integrating with complementary privacy-enhancing technologies 1

1

.

As AI continues to transform the life sciences sector, Apheris's approach could prove instrumental in unlocking the full potential of health data. By addressing data owners' concerns and facilitating secure collaboration, the platform may accelerate AI-driven innovations in drug discovery, personalized medicine, and other critical areas of healthcare research.